Skip to Content

POINT Biopharma Global, Inc.

Merger

  • Date:
  • 10/3/2023
  • Company Name:
  • POINT Biopharma Global, Inc.
  • Stock Symbol:
  • PNT
  • Company Name - Buyer:
  • Eli Lilly and Company
  • Stock Symbol - Buyer:
  • LLY
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 10/3/2023

Case Finder

Locate any case using the tools below.

NEW YORK, October 3, 2023 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of POINT Biopharma Global, Inc. (NASDAQ: PNT) (“POINT”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Eli Lilly and Company (NYSE: LLY) (“Lilly”).

On October 3, 2023, POINT announced that it had entered into an agreement to be acquired by Lilly in a $1.4 billion all-cash deal. Pursuant to the merger agreement, Lilly will acquire all outstanding shares of POINT for a purchase price of $12.50 per share in cash. The purchase price represents a premium of approximately 87% to POINT's closing stock price on Oct. 2, 2023, and 68% to the 30-day volume-weighted average price. The deal is expected to close by the end of 2023.

Bragar Eagel & Squire is concerned that POINT's board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for POINT's stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in POINT Biopharma Global. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: